首页 > 产品中心 > 抗体 > 药物对照抗体

Research Grade Glembatumumab (HC358016)

价格:
规格:
  • 100ug
  • 1mg
数量:
  • 概述
  • 图片
  • 参考文献
  • 产品说明书
概述
货号HC358016
品牌abinScience
种属反应性Human
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主Human
同种型IgG2-kappa
表达系统Mammalian Cells
克隆类型Monoclonal
靶标NMB, Hematopoietic growth factor inducible neurokinin-1 type, HGFIN, GPNMB, Transmembrane glycoprotein NMB
内毒素水平Please contact the lab for this information.
纯度>95% purity as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
Accession号Q14956
状态Liquid
保存溶液0.01M PBS, pH 7.4.
稳定性和存储Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
别名CDX-011(DOX), CR011, glembatumumabvedotin(ADC), 1020264-78-1
背景Glembatumumab (CR011) is a fully human IgG2 monoclonal antibody (mAb) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB, or osteoactivin). It was designed to linke to monomethyl auristatin E (MMAE) via a valine-citrulline enzyme-cleavable linker to act as an antibody-drug conjugate (ADC) termed glembatumumab vedotin (also known as CDX-011 and CR011-vcMMAE) for the treatment of advanced, refractory, or resistant GPNMB-expressing breast cancer. It was originally developed through a partnership between CuraGen and Amgen, using Xenomouse technology licensed from Abgenix and ADC technology licensed from Seattle Genetics. Glembatumumab vedotin was in development through April 2018 by Celldex Therapeutics, who acquired CuraGen in 2009. Development of the ADC was discontinued in April 2018 after missing the primary endpoint of its study and failed to help women with tough-to-treat metastatic triple-negative breast cancers (TNBC) stay both alive and progression-free for longer than Roche Holding AG’s Xeloda (capecitabine).
NoteFor research use only. Not suitable for clinical or therapeutic use.
图片
  • SEC-HPLC

    SEC-HPLC detection for Research Grade Glembatumumab.

  • Bioactivity

    Detects GPNMB in indirect ELISAs.

参考文献

相关产品推荐